Home Your basket
• Parathyroid carcinoma: di...
   Price 5.50 €
• Post-operative evaluation...
   Price 10.50 €
• Anterior cerebrospinal fl...
   Price 10.00 €
• Laryngeal papillomatosis ...
   Price 5.50 €
• Interest of the cervical ...
   Price 10.50 €
• Disorders of the sense of...
   Price 5.50 €
• A new technique for the u...
   Price 5.50 €
• Neuroplasticity in the au...
   Price 10.50 €
• Hearing aids rehabilitati...
   Price 12.50 €
• Hearing disorders at the ...
   Price 12.50 €
• A specific plain X-ray in...
   Price 8.50 €
• Is it possible to evolve ...
   Price 8.50 €
• Gastro-oesophageal reflux...
   Price 8.50 €
• Anatomic evaluation of th...
   Price 10.50 €
• Central auditory processi...
   Price 10.50 €
• Bilateral facial nerve sc...
   Price 10.50 €
• Schwannomas of the neck. ...
   Price 5.50 €
• Using the superficial tem...
   Price 10.50 €
• Osteoblastoma of the eth...
   Price 10.50 €
• Assessing efficacy of voi...
   Price 5.50 €
• Otolaryngological aspects...
   Price 8.50 €
• «Less is more»: A new con...
   Price 14.00 €
• Migrating hypopharyngeal ...
   Price 5.50 €
• Idiopathic sudden deafnes...
   Price 10.50 €
• Unilateral endolymphatic ...
   Price 10.50 €
• Minimising radiation dose...
   Price 5.50 €
• Deafness in adults. Study...
   Price 10.50 €
• Brain stem cavernous angi...
   Price 8.50 €
• Management of free-flap f...
   Price 14.00 €
• Relevance of Choukroun’s ...
   Price 8.50 €
• Alternative clinical mana...
   Price 10.50 €
• A rare case of sarcoidosi...
   Price 5.50 €
• Outcome of surgical and a...
   Price 10.50 €
• The rehabilitation of the...
   Price 10.50 €
• Saddle nose surgery: Long...
   Price 10.50 €
• Hearing preservation in p...
   Price 10.50 €
• Functional septal surgery...
   Price 10.50 €

Total Order 342.00 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 4 - 2008 o

OTONEUROLOGY

Disability in patients with Menière’s disease following the use of two different treatment modalities: Betahistine and intratympanic gentamicin


Authors : Enrique-Gonzalez A, Sánchez-Ferrándiz N, Pérez-Fernández N. (Pamplona)

Ref. : Rev Laryngol Otol Rhinol. 2008;129,4:249-254.

Article published in english
Downloadable PDF document english



Summary : Objective: The objective of this study was to assess the level of residual disability and handicap in patients with Menière’s disease (MD) that were free of new vertigo spells 2 years after having been administered treatment with either oral medication or with intratympanic gentamcin. Setting: University hospital. Tertiary medical center. Material and method: 40 patients with MD were included in this study, of which 20 were treated with oral medication (betahistine) and 20 with intratympanic gentamicin; intratympanic gentamicin was for patients considered failures for the oral medication treatment. All of them are free of new vertigo in the 16-24 month period after beginning the treatment. They were matched by age and disease duration. Disability and handicap were assessed with conventional questionnaires at the time of inclusion and 2 years after beginning oral medication or ended the intratympanic gentamicin treatment. According to the treatment two groups were created: oral medication treatment and intratympanic gentamicin treatment. Results: The amount of disability before treatment was higher in patients treated with intratympanic gentamicin than in those under oral medication; However, after treatment when no more vertigo spells takes place, this disability is significantly reduced and becomes similar for both groups of patients. In patients treated with oral medication the items reflecting the intensity of vertigo spell, the impact of vertigo in daily activities, the perception of quality of life and level of somatization do not show a significant reduction. Conclusion: The number or frequency of vertigo spells are very relevant for the process of disability and handicap of patients with MD when that is low or when oral medication is sufficient to eliminate vertigo spells. However when that number is high and the only possibility to arrest those vertigo spells is the use of intratympanic gentamicin, fear of vertigo must be considered as an associated problem for the patient.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE